Bruce N. Jacobs, Chief Financial Officer at Kymera Therapeutics, Inc. (KYMR), sold 7,613 shares at $42.39 ($318K) on 2024-03-04, disclosed to the SEC on 2024-03-04.
Seasonal sale ($318k) by Chief Financial Officer — this insider has traded KYMR in March in at least three consecutive prior years. Pattern-driven, low signal.
Nothing distinguishes this filing.
| # | Price | Shares | Value | % of Total |
|---|---|---|---|---|
| 1 | $41.41 | 2,378 | $98K | 30.9% |
| 2 | $41.41 | 2,378 | $98K | 30.9% |
| 3 | $42.39 | 1,301 | $55K | 17.3% |
| 4 | $42.39 | 1,301 | $55K | 17.3% |
| 5 | $43.26 | 255 | $11K | 3.5% |
| Total | $41.81 avg | 7,613 |
| $318K |
| 100% |
| Filing → |
| KYMR | SELL | 2025-09-17 | $4.0M | — | Filing → |
| KYMR | SELL | 2025-03-03 | $389K | — | Filing → |
| KYMR | SELL | 2023-03-03 | $42K | — | Filing → |